お知らせ • Feb 11
WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026 WORK Medical Technology Group LTD, Annual General Meeting, Feb 25, 2026, at 09:30 China Standard Time. Location: floor 23, no. 2 tonghuinan road, xiaoshan district, zhejiang province, hangzhou China Reported Earnings • Feb 01
Full year 2025 earnings released Full year 2025 results: US$0.037 loss per share. Revenue: US$9.85m (down 14% from FY 2024). Net loss: US$1.07m (loss narrowed 69% from FY 2024). お知らせ • Jan 01
Hunan Saitumofei Co., Ltd Obtains Manufacturing Approval for Its Ai-Automated Blood Cellorphology Analyzer WORK Medical Technology Group LTD through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co. Ltd. and its subsidiaries in China, announced that its subsidiary, Hunan Saitumofei Co. Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence ("AI")-Automated Human Blood Cell Morphology Analyzer. This regulatory approval represents a milestone in WORK Medical's research and development strategy and is expected to position the Company's new AI-driven device as a key growth catalyst. The analyzer consists of a main unit and embedded analysis software. The main unit integrates an optical imaging system, sample-handling module, barcode scanner, automatic oil-immersion unit, control board, and protective housing. It performs white blood cell differential counts on human blood smears and quantifies morphology parameters of red blood cells and platelets, supporting clinicians in cell morphology screening. Powered by advanced AI automation, the analyzer combines high-speed digital imaging, deep-learning algorithms, and a fully automated workflow to identify, pre-classify, and describe the morphology of white blood cells, red blood cells, and platelets in peripheral blood smears. The analyzer, scheduled to begin manufacturing in the first half of 2026, is designed to enhance efficiency, consistency, and accuracy in microscopic examinations while reducing manual workload and operational costs. お知らせ • Oct 15
WORK Medical Technology Group LTD Announces Receipt of Delisting Determination Letter from Nasdaq WORK Medical Technology Group LTD announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii). Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq. The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025. The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split. お知らせ • Sep 26
WORK Medical Technology Group LTD has filed a Follow-on Equity Offering. WORK Medical Technology Group LTD has filed a Follow-on Equity Offering.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,055,096
Price\Range: $0.075
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 16,944,238
Transaction Features: Registered Direct Offering New Risk • Sep 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 82% per year over the past 5 years. Shareholders have been substantially diluted in the past year (320% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$55.9m market cap). Reported Earnings • Aug 26
First half 2025 earnings released: EPS: US$0.001 (vs US$0.018 in 1H 2024) First half 2025 results: EPS: US$0.001 (down from US$0.018 in 1H 2024). Revenue: US$4.54m (down 14% from 1H 2024). Net income: US$13.2k (down 94% from 1H 2024). Profit margin: 0.3% (down from 4.3% in 1H 2024). The decrease in margin was driven by lower revenue. お知らせ • May 22
WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million. WORK Medical Technology Group LTD has completed a Composite Units Offering in the amount of $5.495 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 10,000,000
Price\Range: $0.5
Discount Per Security: $0.035
Security Name: Pre-Funded Ordinary Units
Security Type: Equity/Derivative Unit
Securities Offered: 10,000,000
Price\Range: $0.0495
Discount Per Security: $0.003465 Board Change • May 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. お知らせ • Apr 13
WORK Medical Technology Group Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency WORK Medical Technology Group LTD (“WORK Medical” or the “Company”), announced that the Company received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") on April 7, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement set in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's Class A ordinary shares for the 30 consecutive business days from February 24, 2025 to April 4, 2025, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until October 6, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company's Class A ordinary shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by October 6, 2025, the Company may be eligible for additional time to regain compliance or may face delisting. The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its Class A ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. お知らせ • Feb 02
WORK Medical Technology Group LTD announced delayed 20-F filing On 01/31/2025, WORK Medical Technology Group LTD announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Jan 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Market cap is less than US$100m (US$70.3m market cap). New Risk • Jan 21
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.6% operating cash flow to total debt). Earnings have declined by 66% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$73.1m market cap). お知らせ • Jan 17
WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025 WORK Medical Technology Group LTD, Annual General Meeting, Feb 05, 2025. お知らせ • Jan 13
Work Medical Technology Group Ltd Announces Board and Committee Changes On December 30, 2024, Mr. Zhongxuan Li, an independent director of WORK Medical Technology Group LTD resigned from the board of directors and each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee of the Board, effective December 30, 2024. Mr. Li’s resignation from the Board and the three committees was due to personal reasons. To fill in the vacancy created by the resignation of Mr. Zhongxuan Li, on January 1, 2025, the Company extended a director offer letter to Mr. Zhenguo Wu, who accepted the offer and signed a consent to act as a director of the Company. On January 9, 2025, the Nominating and Corporate Governance Committee of the Board recommended, and the Board ratified, the appointment of Mr. Zhenguo Wu to serve as an independent director of the Company, a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Nominating and Corporate Governance Committee, effective as of January 1, 2025. Mr. Wu has legal professional experience. He has been a lawyer at Watson & Band Law Offices since December 2024. From April 2021 to November 2024, he served as the board secretary and general counsel at Xuhang Holdings Ltd. From October 2015 to February 2021, he served as the senior vice president of the investment banking division of Shenwan Hongyuan Securities Underwriting and Sponsoring Co. Ltd. Mr. Wu obtained a bachelor’s degree in English from Tangshan Normal University in 2010 and a master’s degree in law from East China University of Political Science and Law in 2013. Board Change • Sep 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Chairman & CEO Shuang Wu is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. お知らせ • Aug 25
WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million. WORK Medical Technology Group LTD has completed an IPO in the amount of $8 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: $4
Discount Per Security: $0.3 
